7月30日，Madrigal Pharmaceuticals盘中下跌12.78%，报476.985美元/股，成交额3.47亿美元。
消息面上，公司于盘前公布第二季度财报。数据显示，Q2产品收入3.64亿美元，超出市场预期的3.53亿美元；每股亏损1.99美元，优于分析师一致预期的2.50美元。核心产品Rezdiffra净销售额同比增长71%，在用患者超4.9万人，较去年同期翻倍以上。然而，每股亏损较去年同期的1.90美元扩大4.74%，净亏损达5793.9万美元。营收与患者增长强劲，但盈利能力边际恶化，市场对盈亏改善节奏存在分歧，叠加生物科技板块整体承压，股价盘中跌幅进一步扩大。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.